Healthcare
Specialist acknowledges efficacy of obesity medications but warns of risks
Endocrinologist Isabel do Carmo advocates for public subsidy of obesity medications like semaglutide and tirzepatide but warns of side effects including muscle and bone mass loss, nutritional deficiencies, and the exacerbation of eating disorders. Currently, these treatments can cost between 130 and 180 euros per month, limiting access for lower-income groups.
Why it matters
If you are considering or currently using obesity medications, be aware of the health risks regarding muscle loss and nutritional deficiencies; if you are seeking these treatments, the lack of current public subsidy means you will likely bear the full cost of 130–180 euros per month.ObservadorRead original ↗
Useful?
